Related Experiment Videos
Diabetes, psychotic disorders and antipsychotic therapy: a consensus statement
Tim J R Lambert1, Leon H Chapman,
1Office for Psychiatric Evaluation and Educational Newmedia, University of Melbourne, Royal Melbourne Hospital, VIC. lambertt@unimelb.edu.au
The Medical Journal of Australia
|November 16, 2004
Summary
Antipsychotic medications, especially newer ones, increase diabetes risk and worsen blood sugar control by causing weight gain and insulin resistance. Active screening and management of metabolic issues are crucial for patients with psychotic illness.
Area of Science:
- Endocrinology
- Psychiatry
- Public Health
Background:
- Psychotic illness and its treatments are linked to higher rates of diabetes and poor blood sugar control.
- Second-generation antipsychotics are more likely than first-generation agents to cause metabolic issues, primarily through weight gain and insulin resistance.
Framework:
- While psychosis management is primary, the high prevalence of metabolic complications necessitates proactive screening and treatment for all patients on antipsychotics.
- A multidisciplinary approach involving primary health practitioners is essential for managing psychosis and its associated medical problems.
Implementation:
- Regular monitoring of weight, blood glucose, lipid levels, and blood pressure is required for patients on antipsychotic agents.
- Early detection and treatment of hyperglycemia and other metabolic problems are critical.
Implications:
- Preventive measures and timely intervention for metabolic disturbances are vital public health strategies.
- Addressing these metabolic sequelae can improve overall health outcomes and reduce morbidity and mortality in individuals with psychosis.